Zealand raises DKK 143m through an offering of new shares

The biotechnology company Zealand Pharma has issued new shares totalling approximately DKK 143m. The shares were offered as an accelerated book-building process. Plesner advised Zealand Pharma on the sale of the shares.

The new increase in the share capital by DKK 143m is to fund Zealand Pharma's continued development of key clinical stage product candidates.

Approximately 2/3 of the new shares were subscribed for by US investors and the remaining 1/3 by European investors.

Zealand Pharma, which was listed on Nasdaq Copenhagen in 2010, is based in Glostrup, Denmark, and has approximately 110 employees, primarily in the areas of research and development.

Latest news on M&A and Capital Markets

Capital Markets